The thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120

Nicos Karasavvas*, Erik Billings, Mangala Rao, Constance Williams, Susan Zolla-Pazner, Robert T. Bailer, Richard A. Koup, Sirinan Madnote, Duangnapa Arworn, Xiaoying Shen, Georgia D. Tomaras, Jeffrey R. Currier, Mike Jiang, Craig Magaret, Charla Andrews, Raphael Gottardo, Peter Gilbert, Timothy J. Cardozo, Supachai Rerks-Ngarm, Sorachai NitayaphanPunnee Pitisuttithum, Jaranit Kaewkungwal, Robert Paris, Kelli Greene, Hongmei Gao, Sanjay Gurunathan, Jim Tartaglia, Faruk Sinangil, Bette T. Korber, David C. Montefiori, John R. Mascola, Merlin L. Robb, Barton F. Haynes, Viseth Ngauy, Nelson L. Michael, Jerome H. Kim, Mark S. De Souza

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

178 Scopus citations

Fingerprint

Dive into the research topics of 'The thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120'. Together they form a unique fingerprint.

Medicine & Life Sciences